Advances and Novel Treatment Options in Metastatic Melanoma

Advances and Novel Treatment Options in Metastatic Melanoma

The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:	Medicine and Nursing ABT-737 acetazolamide acetylcholine adjuvant therapy amoeboid motility angiogenesis apoptosis arthralgia Bcl-2 family BCL2L10 biomarkers BRAF BRAF inhibitor BRAF inhibitors BRAF-mutant melanoma cancer cancer associated fibroblast cancer stem cells carbonic anhydrase cell therapy checkpoint inhibitor cholinergic system combined therapy ctDNA CXCL10 cyclopamine cytokines cytotoxicity diagnosis DOCK4 drug resistance essential oils exosomes extracellular vesicles FAK hedgehog HIPPO HuR immunity immunotherapy interferon invasion ipilimumab lactate dehydrogenase lipid metabolism liquid biopsy liver-directed-therapies machine learning MANS peptide MARCKS mechanism of action melanoma melanoma immune infiltrate melanoma markers melanoma metastasis melanoma PDX melanomagenesis metalloproteinases metastases metastasis metastatic dormancy metastatic therapy metastatic uveal melanoma (mUM) microenvironment microRNAs MITF ML258 motility mucosal melanoma muscarinic receptors n/a nanoparticles nicotinic receptors nivolumab OXPHOS patient stratification PD-1 pembrolizumab phosphorylation plasmacytoid dendritic cells prediction principal component analysis prognosis prognostication protein tyrosine phosphatase PTPs inhibitors Rac1 radiotherapy resistance rheumatoid arthritis sex-hormones sex/gender ShcD adaptor protein siRNA slow cycling phenotype small molecules SOCE STAT3 Support Vector Machine survival target therapy targeted therapy targeted-therapy therapeutic resistance therapy TLR TPC2 tumor microenvironment tumour microenvironment uveal melanoma (UM) WNT5A
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Similar Items

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
by: Ilaria Proietti, et al.
Published: (2020-09-01)

Modern options in personalized therapy of metastatic cutaneous melanoma
by: S A Protsenko, et al.
Published: (2014-09-01)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
by: Ilaria Proietti, et al.
Published: (2020-07-01)

Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma
by: Fabiana Mallone, et al.
Published: (2020-09-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Targeting the ERK Signaling Pathway in Melanoma
by: Paola Savoia, et al.
Published: (2019-03-01)

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
by: Kakadia S, et al.
Published: (2018-10-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Ebner, R., et al.
Published: (2022)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
by: Thomas Jung, et al.
Published: (2021-09-01)

Molecular background of skin melanoma development and progression: therapeutic implications
by: Magdalena Olbryt
Published: (2019-05-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi M, et al.
Published: (2016-05-01)

Phenotype switching in melanoma: implications for progression and therapy
by: Frederic Zhentao Li, et al.
Published: (2015-02-01)

Treatment of Advanced Melanoma: Past, Present and Future
by: Taku Fujimura, et al.
Published: (2020-09-01)

Current State of Target Treatment in BRAF Mutated Melanoma
by: Enrica Teresa Tanda, et al.
Published: (2020-07-01)

The complexity of the ERK/MAP kinase pathway and the treatment of melanoma skin cancer
by: Claudia eWellbrock, et al.
Published: (2016-04-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
by: Bartoušková Marie, et al.
Published: (2020-08-01)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
by: Raphael Reinhard, MD, et al.
Published: (2018-03-01)

BRAF Gene and Melanoma: Back to the Future
by: Margaret Ottaviano, et al.
Published: (2021-03-01)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
by: Valentina Audrito, et al.
Published: (2020-12-01)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF<sup><it>V600D/R</it></sup> mutations
by: Gentilcore Giusy, et al.
Published: (2013-01-01)

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients
by: Sarah Zhou, et al.
Published: (2021-05-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
by: Luca Hegedüs, et al.
Published: (2021-02-01)

Immunological effects of BRAF+MEK inhibition
by: Paolo A. Ascierto, et al.
Published: (2018-09-01)

Targeted therapy; from advanced melanoma to the adjuvant setting
by: Antonio eAhn, et al.
Published: (2013-08-01)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
by: Francesco Spagnolo, et al.
Published: (2021-05-01)

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF<sup>V600</sup> Melanoma via a p53 Dependent Pathway
by: Nancy T. Santiappillai, et al.
Published: (2021-01-01)

Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy
by: Sarah J. Welsh, et al.
Published: (2020-06-01)

Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy
by: Panagiotis Gouveris, et al.
Published: (2021-07-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
by: Francesco Serra, et al.
Published: (2021-08-01)

Implication de la matrice extracellulaire tumorale dans la transition phénotypique et la résistance aux thérapies ciblées du mélanome
by: Ben Jouira, Rania
Published: (2017)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

Therapy for metastatic melanoma: the past, present, and future
by: Finn Laura, et al.
Published: (2012-03-01)

CURRENT CONCEPTS IN THERAPY OF UVEAL MELANOMA
by: Detanac Dženana A, et al.
Published: (2015-07-01)